HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required)
- Response deadline
- Jan 26, 2027 Due in 111 days
- Date posted
- Oct 6, 2026
- Source
- Open notice
Description
The National Institutes of Health (NIH) intends to renew the Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) research network. This renewed network will include several individual research projects supported by one central Coordination Center. The goal of the network is to test new and improved approaches for people who have both chronic pain (CP) and opioid use disorder (OUD). These approaches should lead to meaningful improvements in how health systems deliver care. The network will be part of the NIH’s Helping to End Addiction Long-term (HEAL®) Initiative to speed the development and implementation of scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative will bolster research across NIH to (1) improve treatment and prevention of opioid misuse and OUD and (2) enhance pain management.
Classifications
- NAICS93.213
Documents (1)
- RFA-DA-28-011-Full-Announcement.htmltext/html;charset=UTF-8153 KBNot yet available
Contacts
- impowr@nih.gov301-402-2541
Similar contracts
- HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center (U2C Clinical Trial Not Allowed)Due Jan 26, 2027
- Mind and Body Interventions to Restore Whole Person Health via Emotional Well-Being Mechanisms (R61/R33 Clinical Trial Required)Due Jun 7, 2028
- BRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)Due Nov 8, 2027
- Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)Due Aug 25, 2028
- NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)Due Jan 7, 2028
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)Due Nov 13, 2026